GH Research Showcases Promising Depression Treatment Data at ASCP Meeting

An update from GH Research ( (GHRS) ) is now available.

On May 15, 2025, GH Research PLC announced the acceptance of a Pharmaceutical Pipeline Presentation and late-breaking posters at the upcoming American Society of Clinical Psychopharmacology Annual Meeting. The company will present promising clinical data from a Phase 2b trial of GH001 in treatment-resistant depression, highlighting its potential efficacy and safety. Additionally, results from trials on postpartum depression and bipolar II disorder will be showcased, emphasizing the drug’s rapid onset and substantial efficacy. These developments could significantly impact GH Research’s positioning in the biopharmaceutical industry, offering new hope for patients with difficult-to-treat depressive disorders.

The most recent analyst rating on (GHRS) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.

Spark’s Take on GHRS Stock

According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.

GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.

To see Spark’s full report on GHRS stock, click here.

More about GH Research

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing transformative treatments for depression, specifically targeting treatment-resistant depression (TRD) with its novel and proprietary mebufotenin therapies.

Average Trading Volume: 221,180

Technical Sentiment Signal: Hold

Current Market Cap: $624M

For an in-depth examination of GHRS stock, go to TipRanks’ Stock Analysis page.